Ascendis Pharma A/S (ASND) SEC Filings & Earnings Calls

Regulatory and commercial risks remain; EC decision pending; launch dependent on final approval.

“Forward-looking statements highlight risks: regulatory delays, market acceptance, pricing, competition.”

No material risk identified; routine equity grant.

Minor dilution from warrant exercises, but routine and expected

“210,812 shares issued; share capital increased to DKK 66,400,738”

No financial obligations remain between parties, but Ascendis assumes full development and commercialization risk for the regained programs.

“neither party has any continuing financial obligations to the other.” · word for word

Buyback program is discretionary and may be modified or terminated without notice; no obligation to repurchase specific number of shares.

“The Share Repurchase Program does not require the Company to repurchase any specific number of shares, and may be modified, suspended or terminated at any time without notice.” · word for word

Clinical trial risk: sentinel cohort small (n=7), double-blind portion not yet read out

“seven infants with achondroplasia (mean age 11.7 months) were enrolled in an open-label sentinel cohort” · word for word

Royalty obligations may pressure margins on navepegritide products; dependence on BioMarin IP license.

“royalty payments to BioMarin based on net sales of navepegritide-related products equal to 20% in the United States and 18% in the European Union, South Korea and Brazil” · word for word

Dependence on YORVIPATH for majority of revenue; concentration risk if competition or reimbursement changes.

“YORVIPATH contributed 80% of product revenue in Q2 2026.”

Convertible note settlement completed; no further debt overhang but dilution from conversion may affect EPS.

“All $575M 2.25% Convertible Senior Notes due 2028 converted to equity.”

Potential dilution from warrant exercises

“15,060 warrants granted; 1,524,443 remaining available”

Regulatory risk: EU decision on TransCon CNP monotherapy MAA expected Q4 2026; outcome uncertain

“In the European Union, a decision is anticipated in the fourth quarter of 2026 for the Marketing Authorisation Application for TransCon CNP as a monotherapy for children with achondroplasia.” · word for word

Minimal dilution risk from warrant grant; 14,060 warrants vs. ~66M shares outstanding

“14,060 warrants granted; share capital DKK 66,189,926”

No new safety signals; low ISR rate, no symptomatic hypotension, no acceleration of bone age

“TransCon CNP was generally well tolerated, with a low rate of ISRs (all mild), no symptomatic hypotension, and no acceleration of bone age.” · word for word

Minimal dilution; 177,267 shares vs. ~66M outstanding

“177,267 ordinary shares issued; share capital DKK 66,189,926”

PRV sale is non-recurring; does not reflect ongoing revenue generation

“sale of its Rare Pediatric Disease Priority Review Voucher... for $187.5 million in cash, before transaction-related expenses.” · word for word

No new safety signals; no anti-PTH antibodies developed; low discontinuation rate (89% completed)

“TransCon PTH treatment was generally well-tolerated, with no new safety signals identified... no patients developed anti-PTH antibodies.” · word for word

No new safety signals; one patient developed transient, low-titer, non-neutralizing anti-PTH antibodies with no impact on safety or efficacy

“TransCon PTH treatment was generally well-tolerated, with no new safety signals identified... One patient developed transient, low-titer and non-neutralizing anti-PTH antibodies, with no impact on safety or efficacy.” · word for word

Potential dilution from warrant exercises.

“27,030 warrants granted; 1,553,563 additional warrants available for future grant”

Potential dilution from warrant exercises.

“31,250 warrants granted; 1,580,593 additional warrants available for future grant”

Discontinuation of oncology program may signal pipeline setback, but impact limited as it is not core.

“Decided to discontinue internal development of TransCon IL-2 b/g in Oncology.” · word for word

Dependence on YORVIPATH for revenue concentration; any competitive or regulatory setback could impact growth.

“YORVIPATH revenue €197M out of total €247M, representing ~80% of total revenue.”

Potential equity dilution of up to 3.6 million shares if all convertible notes are converted.

“an aggregate of up to 3,635,840 ordinary shares would be issuable if all of the notes are surrendered for conversion” · word for word

Potential liquidity differences between ADS and ordinary share trading; tax consequences for ADS holders.

“Risks that trading in ordinary shares may be less liquid or result in different trading dynamics; potential adverse tax consequences.”

Regulatory and commercial risks for TransCon CNP outside US.

“EMA decision pending; competition; reimbursement challenges.”

Potential dilution from warrant exercises; minimal near-term impact.

“22,480 warrants granted; 1,644,153 remaining available.”

Continued approval contingent on confirmatory trial verification; commercial execution risk; payer reimbursement uncertainty.

“Continued approval for this indication, which was based on an improvement in annualized growth velocity, may be contingent upon verification and description of clinical benefit in confirmatory trial(s).” · word for word

Regulatory and compliance risk

“If we fail to comply or are found to have failed to comply with EU, FDA and other local regulations related to the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.” · word for word

Tariff risk on operations

“While there can be no assurance that pharmaceuticals will remain free from Reciprocal Tariffs or other trade barriers in the future, we currently believe the impact of the Reciprocal Tariffs on our operations will be immaterial.” · word for word

Dependence on YORVIPATH for majority of revenue; regulatory risk for TransCon CNP PDUFA date Feb 28, 2026.

“TransCon CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026” · word for word

Minimal dilution risk; routine equity compensation.

“16,570 warrants granted; 1,666,633 remaining available.”

Potential dilution from warrant exercises.

“42,030 warrants granted; 1,683,203 remaining available.”

Regulatory risk: TransCon CNP PDUFA and EMA decisions may not be favorable, impacting pipeline value.

“PDUFA goal date of February 28, 2026 for pediatric achondroplasia; EMA decision anticipated Q4 2026” · word for word

Clinical trial risk: Phase 3 basket trial and COACH data may not meet endpoints.

“Initiated Phase 3 basket trial for additional indications; Week 78 COACH data update anticipated Q2 2026” · word for word

Regulatory risk: PDUFA date Feb 28, 2026 for TransCon CNP monotherapy; potential delay or non-approval

“TransCon CNP is under Priority Review by FDA with PDUFA target action date of February 28, 2026” · word for word

Clinical development risk: Phase 3 trial for combination therapy not yet initiated; results may not confirm earlier data

“Ascendis submitted a protocol and held an end of Phase 2 meeting with the FDA regarding a Phase 3 trial” · word for word

Dilution of existing shareholders by ~0.46% from warrant exercises.

“282,197 new shares issued against existing ~61.7M shares outstanding.”

Potential dilution from warrant exercises, though small relative to total shares.

“27,820 warrants granted, each convertible into one ordinary share”

Regulatory delay increases uncertainty for TransCon CNP approval timeline

“FDA extended PDUFA date by 3 months due to major amendment”

Potential dilution from warrant exercises, though small relative to total shares.

“41,220 warrants granted; 1,753,053 remaining available for future grant.”

Foreign currency impact negative €3.6M on YORVIPATH and €1.6M on SKYTROFA.

“YORVIPATH revenue includes negative FX impact of €3.6M; SKYTROFA negative FX impact of €1.6M.”